Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Subscribe
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Subscribe
FREE
Edition
European
US
Oncology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Therapeutic Advances in GI Cancers: Immuno-Oncology and Beyond
November 2024
At the 2024 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain, the latest advancements in immunotherapy for…
Read more
26 Jun 2015
Results of the phase 2 54767414MMY2002 (Sirius) trial of daratumumab for multiple myeloma
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of…
26 Jun 2015
DNMT3A R882 mutations in AML promote chemoresistance and therapeutic relapse
Multivariate analysis of patients with acute myeloid leukaemia (AML) at day 28 in clinical or pathologic complete remission showed that DNMT3A R882…
26 Jun 2015
Updated results from the SORAML trial of sorafenib in younger patients with newly diagnosed AML
The randomised, controlled phase 2 SORAML trial showed that the addition of the tyrosine kinase inhibitor, sorafenib, to chemotherapy improved event-free…
26 Jun 2015
Phase 3 CheckMate 067 trial of nivolumab in previously untreated advanced melanoma
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, Consultant Medical Oncologist at The Royal Marsden…
26 Jun 2015
Whole Brain Radiation Therapy is More Harmful Than Beneficial for Small Brain Metastases
In the phase 3 NCCTG N0574 (Alliance) trial, patients with 1 to 3 small brain metastases were randomised to receive stereotactic radiosurgery (SRS) alone…
26 Jun 2015
Elective Neck Dissection Improved Survival in Early Node-Negative Oral Cancer
A phase 3, randomised controlled trial showed that elective neck dissection improved overall survival by 12.5% and reduced risk of death by 36% when…
26 Jun 2015
Improved Cancer Treatments Linked to Reduced Late Mortality in Childhood Cancer Survivors
Data from the Childhood Cancer Survivor Study (CCSS), a retrospective cohort study of children diagnosed with cancer from 1970–1999 at 31 participating…
26 Jun 2015
Combined Nivolumab and Ipilimumab or Monotherapy Shown Promise in Untreated Melanoma
The randomised, double-blind, phase 3 CheckMate 067 trial showed that nivolumab alone or nivolumab plus ipilimumab significantly improved progression…
Loading posts...
« Previous
1
…
39
40
41
42
43
…
46
Next »